WO2009124119A3 - Phosphodiesterase inhibitors and uses thereof - Google Patents

Phosphodiesterase inhibitors and uses thereof Download PDF

Info

Publication number
WO2009124119A3
WO2009124119A3 PCT/US2009/039129 US2009039129W WO2009124119A3 WO 2009124119 A3 WO2009124119 A3 WO 2009124119A3 US 2009039129 W US2009039129 W US 2009039129W WO 2009124119 A3 WO2009124119 A3 WO 2009124119A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphodiesterase inhibitors
phosphodiesterase
phosphosdiesterase
modulate
bind
Prior art date
Application number
PCT/US2009/039129
Other languages
French (fr)
Other versions
WO2009124119A2 (en
WO2009124119A8 (en
Inventor
Ottavio Arancio
Daniela Puzzo
Donald W. Landry
Shixian Deng
Original Assignee
The Trustes of Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustes of Columbia University in the City of New York filed Critical The Trustes of Columbia University in the City of New York
Priority to EP09835413.7A priority Critical patent/EP2379076B1/en
Priority to JP2011543511A priority patent/JP2012513464A/en
Publication of WO2009124119A2 publication Critical patent/WO2009124119A2/en
Publication of WO2009124119A3 publication Critical patent/WO2009124119A3/en
Publication of WO2009124119A8 publication Critical patent/WO2009124119A8/en
Priority to US13/167,540 priority patent/US8697875B2/en
Priority to US14/224,702 priority patent/US9422242B2/en
Priority to US15/235,736 priority patent/US9974782B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Abstract

The invention provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention further provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject.
PCT/US2009/039129 2008-04-01 2009-04-01 Phosphodiesterase inhibitors and uses thereof WO2009124119A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP09835413.7A EP2379076B1 (en) 2008-12-23 2009-09-29 Phosphodiesterase inhibitors and uses thereof
JP2011543511A JP2012513464A (en) 2008-12-23 2009-09-29 Phosphodiesterase inhibitors and uses thereof
US13/167,540 US8697875B2 (en) 2008-12-23 2011-06-23 Phosphodiesterase inhibitors and uses thereof
US14/224,702 US9422242B2 (en) 2008-12-23 2014-03-25 Phosphodiesterase inhibitors and uses thereof
US15/235,736 US9974782B2 (en) 2008-12-23 2016-08-12 Phosphodiesterase inhibitors and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4145008P 2008-04-01 2008-04-01
US61/041,450 2008-04-01

Publications (3)

Publication Number Publication Date
WO2009124119A2 WO2009124119A2 (en) 2009-10-08
WO2009124119A3 true WO2009124119A3 (en) 2009-12-30
WO2009124119A8 WO2009124119A8 (en) 2010-06-03

Family

ID=41136099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039129 WO2009124119A2 (en) 2008-04-01 2009-04-01 Phosphodiesterase inhibitors and uses thereof

Country Status (1)

Country Link
WO (1) WO2009124119A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
EP2535049A1 (en) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia
US9585558B2 (en) * 2011-12-09 2017-03-07 Regents Of The University Of Minnesota Hyperspectral imaging for early detection of Alzheimer'S Disease
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2013173206A1 (en) * 2012-05-14 2013-11-21 University Of Kansas Phosphonate derivatives for treatment of alzheimer's disease
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
ES2776353T3 (en) 2013-07-17 2020-07-30 Univ Columbia Novel Phosphodiesterase Inhibitors and Uses Thereof
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
MA46995A (en) 2016-12-03 2019-10-09 Acerta Pharma Bv METHODS AND COMPOSITIONS FOR THE USE OF THERAPEUTIC T-LYMPHOCYTES IN COMBINATION WITH KINASE INHIBITORS
CN108409737B (en) * 2017-02-10 2020-07-03 华东理工大学 4-methoxyphenyl substituted tetrahydro- β -carboline piperazine diketone derivative and application thereof
WO2019062733A1 (en) 2017-09-28 2019-04-04 南京药捷安康生物科技有限公司 Pde9 inhibitor and use thereof
KR20230021160A (en) * 2019-03-24 2023-02-13 주식회사 아리바이오 Pharmaceutical chemical composition for recovery of synaptic plasticity

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038168A1 (en) * 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
US20020106676A1 (en) * 2000-10-17 2002-08-08 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative diseases
US20050043325A1 (en) * 2003-04-29 2005-02-24 Pfizer Inc Novel pharmaceuticals
US20050202549A1 (en) * 2001-11-02 2005-09-15 Pfizer Inc Crystal structure
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
US20060281901A1 (en) * 2005-06-14 2006-12-14 Yung Joon Yoo Method for the production of amyloid-beta peptide using ubiquitin
US20070172484A1 (en) * 2002-03-05 2007-07-26 Ramot At Tel-Aviv University Ltd. Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
WO1998038168A1 (en) * 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US20020106676A1 (en) * 2000-10-17 2002-08-08 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative diseases
US20050202549A1 (en) * 2001-11-02 2005-09-15 Pfizer Inc Crystal structure
US20070172484A1 (en) * 2002-03-05 2007-07-26 Ramot At Tel-Aviv University Ltd. Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
US20050043325A1 (en) * 2003-04-29 2005-02-24 Pfizer Inc Novel pharmaceuticals
US20060281901A1 (en) * 2005-06-14 2006-12-14 Yung Joon Yoo Method for the production of amyloid-beta peptide using ubiquitin

Also Published As

Publication number Publication date
WO2009124119A2 (en) 2009-10-08
WO2009124119A8 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2009124119A8 (en) Phosphodiesterase inhibitors and uses thereof
EP2509590A4 (en) Histone acetyltransferase activators and uses thereof
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
HUS1600043I1 (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
WO2011151076A3 (en) Monoclonal antibodies targeting amyloid beta oligomers
WO2007109749A3 (en) Methods for preventing and treating amyloidogenic diseases
IL193695A0 (en) Antibodies against amyloid-beta peptide
IL205502A0 (en) Humanized antibodies against tl1a
PT2152290E (en) Methods for administering anti-il-5 antibodies
EP2009101A4 (en) Antibody modification method for purifying bispecific antibody
ZA201102203B (en) Bispecific anti-vegf/anti/ang-2 antibodies
NZ586754A (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
ZA201001789B (en) Composition and methods for use for antibodies against sclerostin
IL216002A (en) Isolated antibody or antigen-binding fragment thereof which specifically binds to cd100
WO2007071448A3 (en) Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
EP2349331A4 (en) Humanized anti-il-6 antibodies
WO2014074528A3 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules
MX2009004984A (en) Methods for preserving renal function using xanthine oxidoreductase inhibitors.
WO2008038127A3 (en) Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
WO2008124570A8 (en) Methods for inhibiting the binding of endosialin to ligands
WO2010064012A3 (en) Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 )
WO2010138814A3 (en) Disrupting fcrn-albumin interactions
WO2010104598A3 (en) Kinase protein binding inhibitors
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
MX2010004615A (en) Monoclonal antibodies against activated protein c.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09726872

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09726872

Country of ref document: EP

Kind code of ref document: A2